This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
4pdw
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | ''' | + | ==A benzonitrile analogue inhibits rhinovirus replication== |
| + | <StructureSection load='4pdw' size='340' side='right' caption='[[4pdw]], [[Resolution|resolution]] 3.00Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4pdw]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human_rhinovirus_14 Human rhinovirus 14] and [http://en.wikipedia.org/wiki/Rhinovirus_b Rhinovirus b]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PDW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PDW FirstGlance]. <br> | ||
| + | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2XK:4-[(4,5-DIMETHOXY-2-NITROPHENYL)ACETYL]BENZONITRILE'>2XK</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene><br> | ||
| + | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4pdw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4pdw OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4pdw RCSB], [http://www.ebi.ac.uk/pdbsum/4pdw PDBsum]</span></td></tr> | ||
| + | <table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | OBJECTIVES: To study the characteristics and the mode of action of the anti-rhinovirus compound 4-[1-hydroxy-2-(4,5-dimethoxy-2-nitrophenyl)ethyl]benzonitrile (LPCRW_0005). METHODS: The antiviral activity of LPCRW_0005 was evaluated in a cytopathic effect reduction assay against a panel of human rhinovirus (HRV) strains. To unravel its precise molecular mechanism of action, a time-of-drug-addition study, resistance selection and thermostability assays were performed. The crystal structure of the HRV14/LPCRW_0005 complex was elucidated as well. RESULTS: LPCRW_0005 proved to be a selective inhibitor of the replication of HRV14 (EC50 of 2 +/- 1 muM). Time-of-drug-addition studies revealed that LPCRW_0005 interferes with the earliest stages of virus replication. Phenotypic drug-resistant virus variants were obtained (>/=30-fold decrease in susceptibility to the inhibitory effect of LPCRW_0005), which carried either an A150T or A150V amino acid substitution in the VP1 capsid protein. The link between the mutant genotype and drug-resistant phenotype was confirmed by reverse genetics. Cross-resistance studies and thermostability assays revealed that LPCRW_0005 has a similar mechanism of action to the capsid binder pleconaril. Elucidation of the crystal structure of the HRV14/LPCRW_0005 complex revealed the existence of multiple hydrophobic and polar interactions between the VP1 pocket and LPCRW_0005. CONCLUSIONS: LPCRW_0005 is a novel inhibitor of HRV14 replication that acts as a capsid binder. The compound has a chemical structure that is markedly smaller than that of other capsid binders. Structural studies show that LPCRW_0005, in contrast to pleconaril, leaves the toe end of the pocket in VP1 empty. This suggests that extended analogues of LPCRW_0005 that fill the full cavity could be more potent inhibitors of rhinovirus replication. | ||
| - | + | A novel benzonitrile analogue inhibits rhinovirus replication.,Lacroix C, Querol-Audi J, Roche M, Franco D, Froeyen M, Guerra P, Terme T, Vanelle P, Verdaguer N, Neyts J, Leyssen P J Antimicrob Chemother. 2014 Jun 19. pii: dku200. PMID:24948704<ref>PMID:24948704</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | == References == | |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Human rhinovirus 14]] | ||
| + | [[Category: Rhinovirus b]] | ||
| + | [[Category: Franco, D.]] | ||
| + | [[Category: Froeyen, M.]] | ||
| + | [[Category: Guerra, P.]] | ||
| + | [[Category: Lacroix, C.]] | ||
| + | [[Category: Leyssen, P.]] | ||
| + | [[Category: Neyts, J.]] | ||
| + | [[Category: Querol-Audi, J.]] | ||
| + | [[Category: Roche, M.]] | ||
| + | [[Category: Terme, T.]] | ||
| + | [[Category: Vanelle, P.]] | ||
| + | [[Category: Verdaguer, N.]] | ||
| + | [[Category: Benzonitrile inhibitor]] | ||
| + | [[Category: Virus]] | ||
Revision as of 08:23, 2 July 2014
A benzonitrile analogue inhibits rhinovirus replication
| |||||||||||
